Lantern Pharma Inc. (LTRN) Stock Score, Valuation & Financial Research

Lantern Pharma Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LTRN

Lantern Pharma Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.92. These figures are a research snapshot, not a buy or sell recommendation.

What Lantern Pharma Inc. does

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Lantern Pharma is a clinical-stage biopharmaceutical company that utilizes its proprietary RADR artificial intelligence and machine learning platform to identify and develop oncology drug candidates. The company aims to generate revenue through the future commercialization of its drug candidates, potential licensing agreements, and subscription or usage-based fees from its AI platforms like withZeta.ai.

Products and services

  • The company develops a portfolio of AI-driven oncology drug candidates, including LP-184, LP-284, and LP-300, and operates AI platforms RADR and withZeta.ai for drug discovery and development.

Brands and product families

  • RADR — Proprietary AI and machine learning platform for oncology drug discovery. Source
  • withZeta.ai — AI platform designed for subscription and usage-based licensing models. Source

Customer types

Pharmaceutical and biotechnology companies; Academic and research institutions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various unnamed third-party contract research organizations to conduct preclinical and clinical trials. Source
  • Contract Development and Manufacturing Organizations (CDMOs) — The company relies on unnamed third-party contract development and manufacturing organizations for the production of its drug candidates. Source

Business strengths to evaluate

  • Proprietary RADR AI platform for oncology drug discovery Source
  • Experienced management team in drug development and AI Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical research organizations Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LTRN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.92
Market capitalization:
11.75M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -18.65M
Free cash flow:
USD -15.68M
Cash:
USD 6.66M
Total debt:
USD 39.72K
EPS:
USD -1.62

What stands out

  • Free cash flow is USD -15.68M, negative for the stored period.
  • The balance sheet shows USD 6.66M of cash versus USD 39.72K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 6.62M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LTRN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can LTRN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LTRN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LTRN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of LTRN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research LTRN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.